OrderlyMeds Review
We track OrderlyMeds but publish no price for it, and this page explains exactly why.
OrderlyMeds does not publish a tirzepatide price we can interpret and verify from its own material, so we publish none. A figure copied from a third-party round-up without a capture date is not a price, it is a rumour with a dollar sign.
That is not an accusation. Programmes price behind an intake for ordinary commercial reasons. But a comparison site exists to make cost visible before you commit, and a programme that reveals cost only after you have handed over contact details and a health history has opted out of that comparison.
We could not locate a published tirzepatide price for this programme from the provider or any checkable third party, so no figure is published here.
Source
No published price we could verify as of 2026-08-05.
Of the 32 programmes on this site, 11 have a price we read at the provider or manufacturer, 6 carry a third-party figure we have not confirmed, and 15 publish no price we can interpret. Every table shows which is which, because a comparison that mixes them without saying so is not a comparison.
First-year all-in cost
What to ask OrderlyMeds before you give them anything
- What is the total monthly cost at a 10 mg maintenance dose, including every fee?
- Does that figure change as the dose escalates?
- Is there a membership, consultation, shipping or laboratory charge on top?
- Which compounding pharmacy fills the prescription, by name and state licence?
- Is the prescribing clinician licensed in my state?
- What notice is required to cancel, and what is refundable before shipment?
Answers to those six in writing amount to published pricing, and we will record them here with the date. Send them through contact.
Why a missing price is itself information
A programme that publishes a price is making a claim it can be held to. A programme that reveals cost only after an intake has made a commercial choice: it wants contact details and a medical history before you can compare it against anything. That is legal and common, and worth noticing.
It also makes an honest comparison impossible. Every figure on this site is stated all-in at a named dose, and there is no way to place OrderlyMeds on that axis without a number from OrderlyMeds.
What the alternatives publish
The cheapest tracked route, NexLife, publishes $215 a month all-in at a 10 mg maintenance dose and about $2,580 for a first year. Several publish a full ladder from the starter dose to the ceiling. Those figures can be checked against the provider's own page in under a minute, which is the standard OrderlyMeds is being measured against.
What we will not do
Estimate. Several comparison sites carry figures for programmes that publish none, generally by copying an older round-up that copied an earlier one. That is how a promotional rate from two years ago becomes a current price, and it is the most common error in this category.
A blank row is less useful than a number and considerably more honest than a wrong one.
Programmes that do publish a price
Every other programme in our directory states a figure we could capture at at least one dose tier. The cheapest verified all-in cost at a maintenance dose is $215 a month.
How the price behaves as your dose climbs
OrderlyMeds charges — at 2.5 mg and — at 10 mg — the same number. Escalating does not reprice you, so the figure quoted in week one is the figure you pay in month ten. That predictability is worth more than most entry discounts, and it is the single clearest thing this programme does well.
The corollary is that flat pricing is worst value at the bottom of the ladder. In month one you are paying a maintenance rate for an initiation dose. If your prescriber intends to hold you at 5 mg permanently, a dose-scaled competitor may well beat this one.
What a longer horizon costs here
Treatment on this drug class is realistically a multi-year commitment, because the withdrawal evidence shows substantial regain after stopping. These are the numbers worth deciding on.
| If you maintain at | Per month | One year | Three years |
|---|
Commitment, refunds and what is at risk
No discounted prepaid term is published, which cuts both ways: no lower rate for committing, and no money at risk before you know whether you tolerate the drug. For a first three months that is the safer structure.
Cancellation: not published. Two questions to get in writing before paying anything: does the quoted rate hold at renewal, and what happens if a clinician stops your prescription mid-term.
What this programme does not publish
Measured against our published criteria, OrderlyMeds does not publish: price published at every dose tier. Each is a question you can ask before enrolling, and a programme that answers in writing has told you something useful about how it operates.
Naming the dispensing pharmacy carries the most weight of the seven, because it is the only one that lets you check a public state board register yourself before injecting something weekly. Fewer than a fifth of the programmes we price do it.
Seven questions before you enrol
- What is the total in month six at 10 mg, including every fee?
- Which compounding pharmacy fills the prescription, by name and state licence?
- Is the prescribing clinician licensed in my state?
- What is the vial concentration and the beyond-use date?
- Does the quoted rate hold at renewal, or revert?
- What happens if a shipment arrives warm, and who pays for the replacement?
- What notice is required to cancel, and what is refundable before shipment?
None requires clinical training and all are answerable before you pay. A programme that deflects the pharmacy question has answered it.
Using it well if you do enrol
Fix a weekly injection day and keep it. Record dose, date and injection site each week. Photograph any shipment that arrives warm before opening it further. Diary the renewal date if an introductory rate applies. And re-price the market annually at your actual maintenance dose — no programme tells existing patients when a competitor drops below it.
How much orderlymeds should weigh
Less than the dose question and more than the brand. 12 of 16 programmes hold one price from 2.5 mg to 10 mg; the rest reprice as you climb. Which group you choose changes a twelve-month total more than almost any other single decision.
That is because tirzepatide titrates slowly. Eight to twelve weeks minimum to a maintenance dose, frequently longer for tolerability, and a dose-scaled programme reprices you at every step of it.
Flat pricing is worst value at the bottom of the ladder and best at the top, which makes it less a lower price than insurance against a decision your prescriber has not made yet.
What a well-run programme publishes
Its price at every strength. Its pharmacy. Its prescriber's licensure. Its cancellation notice period. And which form of the active ingredient it compounds from, because FDA has distinguished tirzepatide base from salt forms and linked the salts to safety concerns.
That last one is specific to this molecule and almost never asked. Programmes that answer it precisely are telling you how closely they supervise their supply chain.
Why titration is a pricing question
Tirzepatide is started at 2.5 mg weekly and increased in 2.5 mg steps at intervals of at least four weeks. The starter dose is a tolerance-building dose rather than a therapeutic one, and the gastrointestinal effects that cause most discontinuation cluster in the days after each increase.
Reaching a maintenance dose therefore takes at least eight to twelve weeks when nothing is repeated, and repeats are common rather than exceptional. Most of a first year is spent at or near maintenance, which is why every figure on this site is stated at 10 mg and why 12 of the 16 priced programmes holding one price across the ladder is a materially different offer from the rest.
The molecule, and why it costs more than semaglutide
Tirzepatide is a single peptide that activates two incretin receptors: GLP-1, which semaglutide also targets, and GIP, which it does not. Both receptors influence insulin secretion, gastric emptying and central appetite signalling, and the working hypothesis for the larger effect size is that engaging both produces effects the GLP-1 arm alone does not.
That dual action is also part of why it costs more to make. The peptide is longer and more structurally complex than semaglutide, the synthesis is harder, and the active pharmaceutical ingredient sells at a premium to compounding pharmacies. Across programmes carrying both molecules, tirzepatide typically runs forty to a hundred per cent above the same programme's semaglutide price.
The commercial consequence is that a compounded tirzepatide programme has less room to discount than a compounded semaglutide one. When a tirzepatide price looks dramatically below the market, the explanation is usually a promotional rate, a prepaid term or a starting dose rather than a cheaper supply chain.
What the head-to-head trial actually showed
SURMOUNT-5 randomised adults with obesity to tirzepatide or semaglutide and reported a larger mean reduction in body weight on tirzepatide over 72 weeks. It is the strongest direct comparison available and it is the reason many people arrive at this molecule specifically rather than at GLP-1 therapy in general.
Three caveats are worth carrying. A mean is not a prediction for an individual, and the distribution around it is wide. Trial participants received structured support most telehealth programmes do not replicate. And the trial compared maximum tolerated doses, which is a different question from what a given person will tolerate.
Read as a purchasing decision, it says the more expensive molecule does more on average. It does not say it will do more for you, and it says nothing about which programme should supply it.
Why titration is a pricing question
Tirzepatide is started at 2.5 mg weekly and increased in 2.5 mg steps at intervals of at least four weeks. The starter dose is a tolerance-building dose rather than a therapeutic one, and the gastrointestinal effects that cause most discontinuation cluster in the days after each increase.
Reaching a maintenance dose therefore takes at least eight to twelve weeks when nothing is repeated, and repeats are common rather than exceptional. Most of a first year is spent at or near maintenance, which is why every figure on this site is stated at 10 mg and why 12 of the 16 priced programmes holding one price across the ladder is a materially different offer from the rest.
The molecule, and why it costs more than semaglutide
Tirzepatide is a single peptide that activates two incretin receptors: GLP-1, which semaglutide also targets, and GIP, which it does not. Both receptors influence insulin secretion, gastric emptying and central appetite signalling, and the working hypothesis for the larger effect size is that engaging both produces effects the GLP-1 arm alone does not.
That dual action is also part of why it costs more to make. The peptide is longer and more structurally complex than semaglutide, the synthesis is harder, and the active pharmaceutical ingredient sells at a premium to compounding pharmacies. Across programmes carrying both molecules, tirzepatide typically runs forty to a hundred per cent above the same programme's semaglutide price.
The commercial consequence is that a compounded tirzepatide programme has less room to discount than a compounded semaglutide one. When a tirzepatide price looks dramatically below the market, the explanation is usually a promotional rate, a prepaid term or a starting dose rather than a cheaper supply chain.
What the head-to-head trial actually showed
SURMOUNT-5 randomised adults with obesity to tirzepatide or semaglutide and reported a larger mean reduction in body weight on tirzepatide over 72 weeks. It is the strongest direct comparison available and it is the reason many people arrive at this molecule specifically rather than at GLP-1 therapy in general.
Three caveats are worth carrying. A mean is not a prediction for an individual, and the distribution around it is wide. Trial participants received structured support most telehealth programmes do not replicate. And the trial compared maximum tolerated doses, which is a different question from what a given person will tolerate.
Read as a purchasing decision, it says the more expensive molecule does more on average. It does not say it will do more for you, and it says nothing about which programme should supply it.
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.
Compare every programme on one screen
The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.